StockData
Balchem Corp logo

Balchem Corp (BCPC) company profile

BCPCNasdaqChemicals & Allied ProductsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 19/3014% above fair value
$169.63−1.85 (-1.08%)

Close on Nov 17, 2026Market cap $5.39BP/E 31.9Yield 0.57%

About Balchem

Chemicals & Allied Products, SIC 2800

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products across three primary segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The company provides nutrient solutions such as choline, mineral amino acid chelates, specialty vitamins, and food systems to food, beverage, and dietary supplement manufacturers. For animal agriculture and companion pets, it supplies microencapsulated nutrients and choline chloride to livestock and feed producers. In its specialty segment, Balchem packages and distributes performance gases, including ethylene oxide for medical device sterilization and fumigants for agricultural processors, alongside foliar crop nutrients for farmers.

The enterprise operates internationally, serving customers through a direct sales team, independent distributors, and sales agents across global markets. Balchem maintains five gas-filling facilities and employs approximately 1,352 full-time workers worldwide, with manufacturing locations in the United States and Europe, including sites in Italy. The corporation maintains its corporate headquarters in Montvale, New Jersey.

Summary of the business section of Balchem's latest annual report, written by StockData.

Company profile

Company

Legal name
Balchem Corp
Founded
1967
Headquarters
Montvale, NJ
Address
5 Paragon Drive 07645
Phone
(845) 326-5600
Employees
1,352, Dec 31, 2025
Industry
Chemicals & Allied Products
Incorporated in
Maryland
Fiscal year ends
December 31
Auditor
RSM US LLP, New York, New York

Stock & identifiers

Ticker
BCPC
Exchange
Nasdaq
IPO date
Jun 3, 1986
Shares outstanding
32M, Oct 15, 2026
Public float
$5.14B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
3-for-2, Jan 21, 2010; 3-for-2, Jan 22, 2007; 3-for-2, Jan 23, 2006; 3-for-2, Jan 21, 2005; 3-for-2, Jun 4, 1998; 3-for-2, Oct 4, 1994; 4-for-3, Dec 30, 1991; 5-for-4, Dec 31, 1990
SEC CIK
9326
CUSIP
057665200
ISIN
US0576652004
FIGI
BBG000BCY878
Share class FIGI
BBG001S5P2R4
LEI
549300VR70OPMHUI3557
EIN
13-2578432

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Theodore L. HarrisChairman, President & CEO, Director94,403
Ren Anthony GonzalezSVP and Chief R&D Officer7,219
Erin Leigh GilsonChief Accounting Officer2,486
Gunsteren Job Leonard vanSVP and GM, Specialty Products10,149
Hatsuki MiyataEVP, CLO, & Secretary9,232
Frederic BonedSVP/GM, Human Nutri. & Health9,419
Carl Martin BengtssonEVP & Chief Financial Officer29,012
George GrahamSVP and Chief R&D Officer3,220
William A. BackusVP & Chief Accounting Officer7,019
Martin Luther ReidSVP Chief Supply Chain Officer9,615
Michael Brent TignorSVP & Chief HR Officer12,179
Michael Robert SestrickSVP & Chief Technology Officer5,610
David B. FischerDirector9,859
Matthew David WineingerDirector8,012
Daniel E. KnutsonDirector6,899
Monica VicenteDirector2,390
Olivier RigaudDirector2,390
Kathleen B. FishDirector3,429

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.89M$4.92M$2.35M$137$106
FY2024$6.87M$10.37M$1.84M$144$103
FY2023$5.89M$10.94M$1.30M$131$108
FY2022$11.95M$7.98M$1.19M$107$107
FY2021$5.76M$12.20M$1.26M$147$124
FY2020$4.62M$5.61M$1.02M$114$115

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Ted Harris
Chairman, President and Chief Executive Officer
$1.20M$3.15M$1.05M$2.44M$56.18K$7.89M+15%
C. Martin Bengtsson
Executive Vice President and Chief Financial Officer
$614.36K$1.13M$376.18K$818.98K$39.15K$2.97M+24%
Frederic Boned
Senior Vice President and General Manager, Human Nutrition and Health
$542.27K$752.93K$254.05K$671.45K$31.80K$2.25M+20%
Hatsuki Miyata
Executive Vice President, Chief Legal Officer and Secretary
$526.17K$877.88K$293.13K$655.57K$39.62K$2.39M+53%
M. Brent Tignor
Senior Vice President and Chief Human Resources Officer
$446.68K$615.31K$205.19K$476.11K$37.35K$1.78M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed approximately 1,352 full-time employees worldwide, with approximately 16% covered by collective-bargaining agreements.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?